Evidence map›Paper›PMID 38467731›Full record

ArticleEuropean journal of human genetics : EJHG2024

A second hotspot for pathogenic exon-skipping variants in CDC45.

Kelly Schoch, Mischa S G Ruegg, Bridget J Fellows, Joseph Cao, Sabine Uhrig, Stephanie Einsele-Scholz, Saskia Biskup, Samuel R A Hawarden, Vincenzo Salpietro, Valeria Capra and 5 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Identification of a novel and a recurrentFrontiers in genetics · 2026
    Article
  2. Review
  3. Hitting the heights with CiteScore.European journal of human genetics : EJHG · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kelly SchochDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Mischa S G RueggDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
Bridget J FellowsDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.ORCID http://orcid.org/0000-0003-4164-020X
Joseph CaoDivision of Pediatric Radiology, Department of Radiology Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0002-1185-3100
Sabine UhrigInstitute of Clinical Genetics, Klinikum Stuttgart, Stuttgart, Germany.
Stephanie Einsele-ScholzCenter for Human Genetics Tuebingen and CeGaT GmbH, Tuebingen, Germany.
Saskia BiskupCenter for Human Genetics Tuebingen and CeGaT GmbH, Tuebingen, Germany.
Samuel R A HawardenDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Vincenzo SalpietroDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID http://orcid.org/0000-0003-0132-7921
Valeria CapraGenomics and Clinical Genetics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.ORCID http://orcid.org/0000-0002-3097-0388
Undiagnosed Diseases Network
Chris M BrownDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
Andrea AccogliDepartment of Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada.
Vandana ShashiDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Louise S BicknellDepartment of Biochemistry, University of Otago, Dunedin, New Zealand. louise.bicknell@otago.ac.nz.ORCID http://orcid.org/0000-0001-6899-9322

Funding

An integrated and diverse genomic medicine program for undiagnosed diseasesU01HG007672 · NHGRI · DUKE UNIVERSITY · PI SHASHI, VANDANA · 2014 to 2022
$13.4M
An integrated and diverse genomic medicine program for undiagnosed diseasesU01NS134350 · NINDS · DUKE UNIVERSITY · PI VANDANA SHASHI · 2023 to 2026
$3.6M
NHGRI NIH HHS U01 HG007672NINDS NIH HHS U01 NS134350U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) U01HG007672
6 · The paper itself

Abstract

Biallelic pathogenic variants in CDC45 are associated with Meier-Gorlin syndrome with craniosynostosis (MGORS type 7), which also includes short stature and absent/hypoplastic patellae. Identified variants act through a hypomorphic loss of function mechanism, to reduce CDC45 activity and impact DNA replication initiation. In addition to missense and premature termination variants, several pathogenic synonymous variants have been identified, most of which cause increased exon skipping of exon 4, which encodes an essential part of the RecJ-orthologue's DHH domain. Here we have identified a second cohort of families segregating CDC45 variants, where patients have craniosynostosis and a reduction in height, alongside common facial dysmorphisms, including thin eyebrows, consistent with MGORS7. Skipping of exon 15 is a consequence of two different variants, including a shared synonymous variant that is enriched in individuals of East Asian ancestry, while other variants in trans are predicted to alter key intramolecular interactions in α/β domain II, or cause retention of an intron within the 3'UTR. Our cohort and functional data confirm exon skipping is a relatively common pathogenic mechanism in CDC45, and highlights the need for alternative splicing events, such as exon skipping, to be especially considered for variants initially predicted to be less likely to cause the phenotype, particularly synonymous variants.

Indexed as

Cell Cycle ProteinsExonsAlternative SplicingCongenital MicrotiaCraniosynostosesFemaleGrowth DisordersHumansMaleMicrognathismPatellaPedigreeCDC45 protein, humanCell Cycle Proteins

Identifiers

PMID38467731
PMCPMC11219862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.